Sun's FDA Warning Letter

Share this article:
How serious is India's pharma problem?
Sun's FDA Warning Letter

The FDA has given generics maker Sun Pharmaceutical an earful, and publication of its seven-page May 7 Warning Letter—which characterizes the list of infractions as “not intended to be an all-inclusive list of violations and deviations” shows just some of the faults the US regulator has found at a manufacturing site in Gujarat, India.

Sun—and now-subsidiary Ranbaxy—have been a growing source of tension for reasons that include manufacturing problems that have triggered recalls, FDA manufacturing site bans, and claims by officials that India has been unfairly picked on by US regulatory authorities.

The May 7 letter provides insight as to some of the issues the FDA wants ironed out, which could come under the broad heading of don't destroy documents or try to hide unfavorable information.

Among the issues: failure to ensure lab records included complete data, deleting data files and declaring samples that did not meet FDA requires as “unofficial tests,” as well as reporting only good testing data as “official” from a sample batch.

FDA inspectors also found about 10 garbage bags filled with partially destroyed manufacturing documentation. This is in addition to finding partially destroyed corrective action documentation as well as Sun's failure to train staff about proper practices.

The FDA says Sun's attempts to investigate issues such as file deletion have been inadequate; that the company has failed not only to explain the negative testing results it uncovered but also “to justify the basis of your decision to invalidate the original failing.”

This is in addition to finding “three partially filled unidentified bags...in your firm's raw material warehouse,” and the fact that employees “were unable to determine conclusively the identity or status of the material.”

The regulator's letter notes that this is not the first time Sun has seen these complaints. The FDA notes that the firm's initial response, as well as those of January 28, 2014, and March 11, 2014, “lack sufficient corrective actions.”

The FDA said it may continue to ban drugs manufactured at the site if Sun fails to fix things according to the FDA's requirements.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...